Leonardo Clavijo, MD
Interventional Cardiology · Saint Helena, CANPI 1225088537
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Cook Incorporated at 52.6% of the total. Reporting peaked in 2022 at $10,167 and has fallen 73.9% since, to $2,650 in 2025.
Across 155 payments — averaging $168.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$14K
- Medtronic$3K
- Boston Scientific$2K
- Inari Medical, Inc.$2K
- Cook Medical LLC$1K
- Amgen$1K
- plus $3K from 16 others
Across 55 payments — averaging $20,611 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.1M
- Boston Scientific$33K
- Philips North America LLC$11K
- AstraZeneca$7K
- Atricure, Inc.$5K
- Abbott$4K
- plus $6K from 3 others
What the payments were for
- Speaking & faculty fees$13,69553%
- Travel & lodging$4,81018%
- Food & beverage$7,52929%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 3 | $13,695 |
| Medtronic | 29 | $2,637 |
| Boston Scientific | 40 | $1,968 |
| Inari Medical, Inc. | 6 | $1,537 |
| Cook Medical LLC | 12 | $1,461 |
| Amgen | 6 | $1,432 |
| Abbott | 20 | $1,181 |
| Stryker | 6 | $523 |
| Philips North America LLC | 11 | $473 |
| Impulse Dynamics (USA) Inc. | 2 | $271 |
| Janssen Scientific Affairs, LLC | 2 | $235 |
| Abiomed | 3 | $201 |
| Biotronik Inc. | 3 | $164 |
| Novartis | 1 | $89 |
| Cordis US CORP. | 2 | $38 |
| Edwards Lifesciences | 1 | $31 |
| GE HealthCare | 2 | $30 |
| Acist Medical Systems, Inc. | 2 | $28 |
| Biosense Webster, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Endologix LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micropuncture$7,095
- Cook Medical Angioplasty$4,800
- ADVANCE$1,938
- FLOWTRIEVER CATHETER, S$1,671
- CT THROMBECTOMY SYSTEM KIT$1,671
- Repatha$1,342
- Valiant Captivia$615
- Cook$468
- MitraClip$455
- Cook Medical Peripheral Intervention$409
- FlowTriever$309
- WATCHMAN Access System$294
- EMBLEM$274
- OPTIMIZER$271
- AZURE XT DR MRI SURESCAN$242
- XARELTO$235
- GENERAL - THERAPIES$208
- VenaSeal$140
- Impella$135
- CardioMEMS HF System$134
How this compares
$26,060 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 203 | $189,908 |
| EntrestoSacubitril/Valsartan | 48 | $52,614 |
| XareltoRivaroxaban | 38 | $41,941 |
| JardianceEmpagliflozin | 23 | $22,308 |
| Repatha SureclickEvolocumab | 32 | $19,585 |
| Metoprolol Succinate | 282 | $5,210 |
| Ezetimibe | 86 | $2,699 |
| ClopidogrelClopidogrel Bisulfate | 203 | $2,640 |
| Atorvastatin Calcium | 151 | $2,303 |
| Potassium Chloride | 66 | $2,158 |
| Rosuvastatin Calcium | 132 | $2,008 |
| Ranolazine ErRanolazine | 15 | $1,715 |
| Flecainide Acetate | 35 | $1,561 |
| Carvedilol | 89 | $1,177 |
| Losartan Potassium | 81 | $1,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $89 | $52,61448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Saint Helena
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.